Safety and tolerability
ADVERSE EVENTS, ADVERSE EVENT
Safety evaluation of NMN supplementation was to assess if NMN would cause significant changes to clinical lab parameters from blood and urinary samples and to adverse events (AE) when compared to placebo and baseline. Clinical lab tests of blood and urinary samples were conducted at baseline and day 60. The lab clinical tests at 1st visit for screening served as baseline. Physical examination of general and systematic exam and vital signs was conducted, documented, and analyzed for safety concern at each visit. Adverse events (AE) were also monitored, recorded, and analyzed for NMN supplementation-related safety issues throughout the course of trial. Tolerability study was conducted through the comparison analysis of treatment vs. placebo on the number of dropout due to AEs.